PCV8 Cost-Effectiveness and Budget Impact Analysis of Rivaroxaban in the Prevention of Thromboembolic Events in Patients Performing Hip and Knee Arthroplasty in Comparison with Dabigatran Under the Brazilian Private Health Care System Perspective [PDF]
, 2011 Alexandre Schiola +6 more
openalex +1 more source
Dabigatran como posibilidad terapéutica en el síndrome de trombocitopenia inducida por heparina tipo II [PDF]
, 2012 F. J. Anniccherico +3 more
openalex +1 more source
PCV2 Comparative Efficacy and Safety Analysis of Atrial Fibrillaion Patients Treated with Dabigatran in RE-LY Study (CHADS 2 Score of 3 or Greater ) Versus Rivaroxaban in ROCKET-AF [PDF]
, 2012 S. Rasty, W. Soliman, Reza Taheri
openalex +1 more source
Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study [PDF]
, 2015 BACKGROUND & AIMS: Use of dabigatran, an inhibitor of thrombin, increases the risk of gastrointestinal bleeding (GIB). However, it is not clear whether gastroprotective agents (GPAs) prevent GIB in dabigatran users.
Chan, EW +6 more
core
Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate [PDF]
, 2012 Melissa D. Lambourne +5 more
openalex +1 more source
Perspective on dabigatran etexilate dosing: why not follow standard pharmacological principles? [PDF]
, 2012 Paul K. L. Chin +3 more
openalex +1 more source
Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin [PDF]
, 2012 Jeff S. Healey +12 more
openalex +1 more source